Showing 7 posts of 112 posts found.

Biogen Idec buys neurodegenerative disease rights

December 21, 2010
Research and Development Alzheimer's, Alzheimer's disease, Alzheimer’s, Alzheimer’s disease, Biogen, Biogen IDEC, Neurimmune, Parkinson's disease, Parkinson’s disease, amyotrophic lateral sclerosis, neurodegenerative diseases

Biogen Idec has acquired a subsidiary of Swiss biotech company Neurimmune, and the rights to three pre-clinical immunotherapy drugs. The …

Biogen set to axe 650 jobs and focus on neurology

November 4, 2010
Research and Development, Sales and Marketing Biogen, Rituxan, job cuts, pharma jobs

Biogen Idec is set to cut hundreds of jobs and refocus its R&D in an effort to cut costs by …


George Scangos to head up Biogen

July 7, 2010
Research and Development Biogen, appointment, research and development

Biogen Idec has appointed George Scangos chief executive officer, with effect from 15 July. Scangos will join the company from …

Abbott sign

Abbott starts head-to-head MS trial

May 25, 2010
Research and Development, Sales and Marketing Abbott, Avonex, Biogen, Gilena, daclizumab

Abbott has started enrolment for a phase III trial of daclizumab, a once-monthly injection for relapsing-remitting multiple sclerosis that it …

Awards recognise top pharma manufacturing projects

January 19, 2010
Manufacturing and Production Biogen, Genentech, Mannkind, Pfizer

The winners of the 2010 Facility of the Year Awards have been made public, with Pfizer grabbing two out of …

Biogen submits Fampridine PR to European regulators

January 14, 2010
Sales and Marketing Biogen, Fampridine, MS

Biogen Idec is seeking European approval for a drug which helps multiple sclerosis sufferers to walk better. A marketing authorisation …

Mixed news for Biogen Idec on Tysabri

April 27, 2009
Manufacturing and Production Biogen

Biogen Idec has won approval for a new high-titre manufacturing process for its multiple sclerosis product Tysabri (natalizumab) which should …

Latest content